|
|
Blood, Vol. 112, Issue 8, 3412-3424, October 15, 2008
High-resolution whole genome tiling path array CGH analysis of CD34+ cells from patients with low-risk myelodysplastic syndromes reveals cryptic copy number alterations and predicts overall and leukemia-free survival
Blood Starczynowski et al.
112: 3412
Supplemental materials for: Starczynowski et al
Files in this Data Supplement:
- Table S1. Patient population characteristics (PDF, 165 KB)
- Table S2. Individual clinical characteristics of the MDS patients used in the aCGH analysis (PDF, 0.98 MB)
- Table S3. Recurrent alterations detected by array CGH in MDS samples (PDF, 311 KB)
- Table S4. ACGH analysis of CD34+ bone marrow cells from age-matched normal controls (PDF, 561 KB)
- Figure S1. Representative array CGH log ratio plots of CD34+, PB, and CD3+ cells of two MDS patients (JPG, 329 KB)
-
(A) A high level amplification (log2 signal intensity >1) is detected on chr 11q24.2-qter in CD34+ and peripheral blood mononuclear cells (PB) cells, but not in CD3+ cells, from Patient #1. (B) Loss of the entire chromosome 7 is detected in CD34+ and PB cells, but not CD3+ cells, from Patient #22 (left). Chromosome 8 is diploid in CD34+, PB, and CD3+ cells of the same patient (Right). Normalized log2 signal intensity ratios were plotted and visualized by SeeGH.Vertical lines denote log2 signal ratios from −1 to +1. Copy number increases are shown to the right and decreases are shown to the left of 0. Each black dot represents a single BAC clone. A: amplification/gain; L: loss/deletion; N: normal/diploid.
- Figure S2. Overall survival of de novo lower-risk MDS patients predicted by total genomic alterations (TGA) (JPG, 70.4 KB)
-
Overall (A and C) and AML-free (B and D) survival was determined when patients were stratified by TGA (A and B) or IPSS score (C and D). Numbers in parentheses represent the number of patients in each group.
|
|
